Literature DB >> 30870839

Dysregulated Expression of Tim-3 and NKp30 Receptors on NK Cells of Patients with Chronic Lymphocytic Leukemia.

Leila Hadadi1, Morteza Hafezi2, Ali Akbar Amirzargar3, Ramazan Ali Sharifian4, Saeid Abediankenari1,5, Hossein Asgarian-Omran6,7.   

Abstract

BACKGROUND: In this study, the expression pattern of NKp30 and T cell immunoglobulin and mucin domain-containing molecule-3 (Tim-3), as candidates for activating and inhibitory receptors of NK cells, were evaluated in patients with chronic lymphocytic leukemia (CLL). PATIENTS AND METHODS: 24 CLL patients and 19 healthy controls were enrolled. Fresh peripheral blood was collected from all subjects and stained with fluorochrome-conjugated antibodies. The frequency of CD56+/CD3-/NKp30+ and CD56+/CD3-/Tim-3+ cells was determined by multicolor flow cytometry.
RESULTS: Our results revealed that Tim-3 is significantly upregulated on natural killer (NK) cells of CLL patients in comparison to healthy controls. NK cells of CLL patients showed lower expression of NKp30-activating receptor compared to controls. Tim-3 expression pattern on NK cells of CLL patients was correlated with poor prognostic factors including low hemoglobin level, high absolute lymphocyte count, and high serum C-reactive protein level.
CONCLUSION: Dysregulated expression of Tim-3 and NKp30 receptors confirms the exhaustion state of NK cells in CLL. Our data introduce Tim-3 as a promising biomarker and potential target for immunotherapy of CLL.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Chronic lymphocytic leukemia; NK cells; NKp30; Tim-3

Mesh:

Substances:

Year:  2019        PMID: 30870839     DOI: 10.1159/000497208

Source DB:  PubMed          Journal:  Oncol Res Treat        ISSN: 2296-5270            Impact factor:   2.825


  11 in total

1.  Association of Mast Cell Burden and TIM-3 Expression with Recalcitrant Chronic Rhinosinusitis with Nasal Polyps.

Authors:  Michael A Belsky; Erica Corredera; Hridesh Banerjee; John Moore; Li Wang; Lawrence P Kane; Stella E Lee
Journal:  Ann Otol Rhinol Laryngol       Date:  2021-02-12       Impact factor: 1.973

Review 2.  NK Cells in the Treatment of Hematological Malignancies.

Authors:  Ana P Gonzalez-Rodriguez; Mónica Villa-Álvarez; Christian Sordo-Bahamonde; Seila Lorenzo-Herrero; Segundo Gonzalez
Journal:  J Clin Med       Date:  2019-09-27       Impact factor: 4.241

Review 3.  Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies.

Authors:  Massimo Giuliani; Alessandro Poggi
Journal:  Cells       Date:  2020-06-29       Impact factor: 6.600

Review 4.  Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.

Authors:  Valentina Griggio; Francesca Perutelli; Chiara Salvetti; Elia Boccellato; Mario Boccadoro; Candida Vitale; Marta Coscia
Journal:  Front Immunol       Date:  2020-11-18       Impact factor: 7.561

Review 5.  Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges.

Authors:  Alessandro Poggi; Maria Raffaella Zocchi
Journal:  Mol Ther Oncolytics       Date:  2021-11-29       Impact factor: 7.200

Review 6.  The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors.

Authors:  Rodion A Velichinskii; Maria A Streltsova; Sofya A Kust; Alexander M Sapozhnikov; Elena I Kovalenko
Journal:  Int J Mol Sci       Date:  2021-10-21       Impact factor: 5.923

Review 7.  NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.

Authors:  Paolo Sportoletti; Filomena De Falco; Beatrice Del Papa; Stefano Baldoni; Valerio Guarente; Andrea Marra; Erica Dorillo; Chiara Rompietti; Francesco Maria Adamo; Loredana Ruggeri; Mauro Di Ianni; Emanuela Rosati
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923

Review 8.  Targeted Therapies: Friends or Foes for Patient's NK Cell-Mediated Tumor Immune-Surveillance?

Authors:  Laura Damele; Selene Ottonello; Maria Cristina Mingari; Gabriella Pietra; Chiara Vitale
Journal:  Cancers (Basel)       Date:  2020-03-25       Impact factor: 6.639

Review 9.  Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.

Authors:  Yuqing Cao; Xiaoyu Wang; Tianqiang Jin; Yu Tian; Chaoliu Dai; Crystal Widarma; Rui Song; Feng Xu
Journal:  Signal Transduct Target Ther       Date:  2020-10-29

10.  Expression Analysis of Fyn and Bat3 Signal Transduction Molecules in Patients with Chronic Lymphocytic Leukemia.

Authors:  Fereshteh Hosseini-Valiki; Saeid Taghiloo; Golvash Tavakolian; Omolbanin Amjadi; Mohsen Tehrani; Akbar Hedayatizadeh-Omran; Reza Alizadeh-Navaei; Ehsan Zaboli; Ramin Shekarriz; Hossein Asgarian-Omran
Journal:  Asian Pac J Cancer Prev       Date:  2020-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.